|
1
|
Ferlay J, Autier P, Boniol M, Heanue M,
Colombet M and Boyle P: Estimates of the cancer incidence and
mortality in Europe in 2006. Ann Oncol. 18:581–592. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
3
|
Dhar DK, Yoshimura H, Kinukawa N, et al:
Metastatic lymph node size and colorectal cancer prognosis. J Am
Coll Surg. 200:20–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kalluri R: EMT: when epithelial cells
decide to become mesenchymal-like cells. J Clin Invest.
119:1417–1419. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ponta H, Sherman L and Herrlich PA: CD44:
from adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dalerba P, Dylla SJ, Park IK, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zoller M: CD44: can a cancer-initiating
cell profit from an abundantly expressed molecule? Nat Rev Cancer.
11:254–267. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Finke LH, Terpe HJ, Zorb C, Haensch W and
Schlag PM: Colorectal cancer prognosis and expression of
exon-v6-containing CD44 proteins. Lancet. 345:5831995. View Article : Google Scholar
|
|
13
|
Mulder JW, Kruyt PM, Sewnath M, et al:
Colorectal cancer prognosis and expression of exon-v6-containing
CD44 proteins. Lancet. 344:1470–1472. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peng J, Lu JJ, Zhu J, et al: Prediction of
treatment outcome by CD44v6 after total mesorectal excision in
locally advanced rectal cancer. Cancer J. 14:54–61. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wielenga VJ, Heider KH, Offerhaus GJ, et
al: Expression of CD44 variant proteins in human colorectal cancer
is related to tumor progression. Cancer Res. 53:4754–4756.
1993.PubMed/NCBI
|
|
16
|
Kobel M, Weichert W, Cruwell K, Schmitt
WD, Lautenschlager C and Hauptmann S: Epithelial hyaluronic acid
and CD44v6 are mutually involved in invasion of colorectal
adenocarcinomas and linked to patient prognosis. Virchows Arch.
445:456–464. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kammula US, Kuntz EJ, Francone TD, et al:
Molecular co-expression of the c-Met oncogene and hepatocyte growth
factor in primary colon cancer predicts tumor stage and clinical
outcome. Cancer Lett. 248:219–228. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang WG, Lloyds D, Puntis MC, Nakamura T
and Hallett MB: Regulation of spreading and growth of colon cancer
cells by hepatocyte growth factor. Clin Exp Metastasis. 11:235–242.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uchiyama A, Essner R, Doi F, et al:
Interleukin 4 inhibits hepatocyte growth factor-induced invasion
and migration of colon carcinomas. J Cell Biochem. 62:443–453.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Di Renzo MF, Olivero M, Giacomini A, et
al: Overexpression and amplification of the met/HGF receptor gene
during the progression of colorectal cancer. Clin Cancer Res.
1:147–154. 1995.PubMed/NCBI
|
|
21
|
Wielenga VJ, van der Voort R, Taher TE, et
al: Expression of c-Met and heparan-sulfate proteoglycan forms of
CD44 in colorectal cancer. Am J Pathol. 157:1563–1573. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weidner KM, Sachs M and Birchmeier W: The
Met receptor tyrosine kinase transduces motility, proliferation,
and morphogenic signals of scatter factor/hepatocyte growth factor
in epithelial cells. J Cell Biol. 121:145–154. 1993. View Article : Google Scholar
|
|
23
|
Bladt F, Riethmacher D, Isenmann S, Aguzzi
A and Birchmeier C: Essential role for the c-met receptor in the
migration of myogenic precursor cells into the limb bud. Nature.
376:768–771. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Orian-Rousseau V, Chen L, Sleeman JP,
Herrlich P and Ponta H: CD44 is required for two consecutive steps
in HGF/c-Met signaling. Genes Dev. 16:3074–3086. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van der Voort R, Taher TE, Wielenga VJ, et
al: Heparan sulfate-modified CD44 promotes hepatocyte growth
factor/scatter factor-induced signal transduction through the
receptor tyrosine kinase c-Met. J Biol Chem. 274:6499–6506.
1999.
|
|
26
|
Takahashi E, Nagano O, Ishimoto T, et al:
Tumor necrosis factor-alpha regulates transforming growth
factor-beta-dependent epithelial-mesenchymal transition by
promoting hyaluronan-CD44-moesin interaction. J Biol Chem.
285:4060–4073. 2010. View Article : Google Scholar
|
|
27
|
Edge SB, Byrd BD and Compton CC: AJCC
Cancer Staging Manual. 7th edition. Springer; New York, NY:
2010
|
|
28
|
Okabe H, Beppu T, Hayashi H, et al:
Hepatic stellate cells may relate to progression of intrahepatic
cholangiocarcinoma. Ann Surg Oncol. 16:2555–2564. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Okabe H, Beppu T, Ueda M, Hayashi H,
Ishiko T, Masuda T, Otao R, Horlad H, Mima K, Miyake K, Iwatsuki M,
Baba Y, Takamori H, Jono H, Shinriki S, Ando Y and Baba H:
Identification of CXCL5 involved in the interaction between
cholangiocarcinoma and cancer associated fibroblasts. Int J Cancer.
131:2234–2241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grotegut S, von Schweinitz D, Christofori
G and Lehembre F: Hepatocyte growth factor induces cell scattering
through MAPK/Egr-1-mediated upregulation of Snail. EMBO J.
25:3534–3545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huh JW, Kim HR, Kim YJ, et al: Expression
of standard CD44 in human colorectal carcinoma: association with
prognosis. Pathol Int. 59:241–246. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ichikawa W: Positive relationship between
expression of CD44 and hepatic metastases in colorectal cancer.
Pathobiology. 62:172–179. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Visca P, Del Nonno F, Botti C, et al: Role
and prognostic significance of CD44s expression in colorectal
cancer. Anticancer Res. 22:2671–2675. 2002.PubMed/NCBI
|
|
34
|
Fernandez JC, Vizoso FJ, Corte MD, et al:
CD44s expression in resectable colorectal carcinomas and
surrounding mucosa. Cancer Invest. 22:878–885. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heider KH, Hofmann M, Hors E, et al: A
human homologue of the rat metastasis-associated variant of CD44 is
expressed in colorectal carcinomas and adenomatous polyps. J Cell
Biol. 120:227–233. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ylagan LR, Scholes J and Demopoulos R:
CD44: a marker of squamous differentiation in adenosquamous
neoplasms. Arch Pathol Lab Med. 124:212–215. 2000.PubMed/NCBI
|
|
37
|
Furuta K, Zahurak M, Goodman SN, Hamilton
SR and August JT: CD44 expression in the stromal matrix of
colorectal cancer: association with prognosis. Clin Cancer Res.
4:21–29. 1998.PubMed/NCBI
|
|
38
|
Nanashima A, Yamaguchi H, Sawai T, et al:
Prognostic factors in hepatic metastases of colorectal carcinoma:
immunohistochemical analysis of tumor biological factors. Dig Dis
Sci. 46:1623–1628. 2001. View Article : Google Scholar
|
|
39
|
Nanashima A, Yamaguchi H, Sawai T, et al:
Expression of adhesion molecules in hepatic metastases of
colorectal carcinoma: relationship to primary tumours and prognosis
after hepatic resection. J Gastroenterol Hepatol. 14:1004–1009.
1999. View Article : Google Scholar
|
|
40
|
Zlobec I, Gunthert U, Tornillo L, et al:
Systematic assessment of the prognostic impact of membranous CD44v6
protein expression in colorectal cancer. Histopathology.
55:564–575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gunther K, Dworak O, Remke S, et al:
Prediction of distant metastases after curative surgery for rectal
cancer. J Surg Res. 103:68–78. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gotley DC, Fawcett J, Walsh MD, Reeder JA,
Simmons DL and Antalis TM: Alternatively spliced variants of the
cell adhesion molecule CD44 and tumour progression in colorectal
cancer. Br J Cancer. 74:342–351. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Koretz K, Moller P, Lehnert T, Hinz U,
Otto HF and Herfarth C: Effect of CD44v6 on survival in colorectal
carcinoma. Lancet. 345:327–328. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Neumayer R, Rosen HR, Reiner A, et al:
CD44 expression in benign and malignant colorectal polyps. Dis
Colon Rectum. 42:50–55. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kuhn S, Koch M, Nubel T, et al: A complex
of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins
promotes colorectal cancer progression. Mol Cancer Res. 5:553–567.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu YJ, Yan PS, Li J and Jia JF:
Expression and significance of CD44s, CD44v6, and nm23 mRNA in
human cancer. World J Gastroenterol. 11:6601–6606. 2005.PubMed/NCBI
|
|
47
|
Bendardaf R, Elzagheid A, Lamlum H,
Ristamaki R, Collan Y and Pyrhonen S: E-cadherin, CD44s and CD44v6
correlate with tumour differentiation in colorectal cancer. Oncol
Rep. 13:831–835. 2005.PubMed/NCBI
|
|
48
|
Tremmel M, Matzke A, Albrecht I, et al: A
CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and
angiogenesis. Blood. 114:5236–5244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Brown RL, Reinke LM, Damerow MS, et al:
CD44 splice isoform switching in human and mouse epithelium is
essential for epithelial-mesenchymal transition and breast cancer
progression. J Clin Invest. 121:1064–1074. 2011. View Article : Google Scholar
|
|
50
|
Kuniyasu H, Oue N, Tsutsumi M, Tahara E
and Yasui W: Heparan sulfate enhances invasion by human colon
carcinoma cell lines through expression of CD44 variant exon 3.
Clin Cancer Res. 7:4067–4072. 2001.PubMed/NCBI
|
|
51
|
Yamaguchi A, Urano T, Goi T, et al:
Expression of a CD44 variant containing exons 8 to 10 is a useful
independent factor for the prediction of prognosis in colorectal
cancer patients. J Clin Oncol. 14:1122–1127. 1996.PubMed/NCBI
|
